Close Menu

VolitionRx

A portion of the funding, which is from the government of the Wallonia region of Belgium, is repayable over 12 years.

VolitonRx's research-use-only kits can be used to examine patterns in circulating nucleosomes in disease models, preclinical testing, and clinical trials.

The test combines two previously CE marked assays that are based on the company's Nucleosomics platform for identifying and quantifying nucleosome structural features.

The company also plans to get started this year on preparations for bringing future tests through the US Food and Drug Administration.

The company is working with DKFZ to evaluate its NuQ test, which can identify chromosome fragments circulating in blood and analyze them for epigenetic modifications.

The tests are based on the company's Nucleosomics platform for identifying and quantifying nucleosome structural features such as histone modifications.

The blood-based assay, which uses the company's nucleosome detection technology, is the first of several that will be bundled together as a test for cancer diagnosis.

The study will evaluate the ability of VolitionRx's technology to detect prostate cancer and to distinguish different prostate conditions and healthy samples.

The IP covers the detection of histone modifications in cell-free nucleosomes from circulating cancer cells.

The firm closed its offering of 2,475,000 shares of stock at a price of $3.75 per share. It plans to use the proceeds to fund colorectal cancer clinical trials. 

Pages

Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.

A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.

In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.